Quote:
Originally Posted by lady_express_44
The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive)."
|
Another thing that is really exciting about this treatment, is the PRIMARY ENDPOINT will be measured by
disability progression, not number of relapses and/or enhancing lesions. That means this might significantly impact the overall disease process, unlike the CRABs and Tysabri which focus their success mostly on the inflammatory process (a more transient measure of the disease).
Cherie
__________________
I am not a Neurologist, Physician, Nurse, or Hairdresser ... but I have learned that it is not such a great idea to give oneself a haircut after three margaritas
.